Amundi Grows Stock Position in LivaNova PLC $LIVN

Amundi increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 7.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 196,435 shares of the company’s stock after buying an additional 13,142 shares during the quarter. Amundi owned about 0.36% of LivaNova worth $7,362,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Central Pacific Bank Trust Division lifted its position in LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock worth $173,000 after buying an additional 290 shares in the last quarter. CWM LLC lifted its position in LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company’s stock worth $34,000 after buying an additional 299 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its position in LivaNova by 2.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company’s stock worth $817,000 after buying an additional 500 shares in the last quarter. UMB Bank n.a. lifted its position in LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company’s stock worth $33,000 after buying an additional 647 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in LivaNova by 13.4% in the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock valued at $258,000 after purchasing an additional 790 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the topic of a number of research analyst reports. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research report on Tuesday, May 20th. Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Barclays lifted their price objective on LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $59.71.

LivaNova Trading Down 3.7%

NASDAQ:LIVN opened at $56.52 on Thursday. The stock has a 50-day simple moving average of $49.41 and a 200-day simple moving average of $43.89. The stock has a market cap of $3.09 billion, a P/E ratio of -14.53 and a beta of 0.97. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $58.91. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analysts’ expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 EPS. As a group, analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.